Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2811376 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs LY 2811376 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 16 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.